Elber S. Camacho - Concepedia

Concepedia

Author

Elber S. Camacho

Cancer Research And Biostatistics

Also Known As

E CAMACHO, E S Camacho, E. Camacho, Elber Camacho, Elber S Camacho, Elber S. Camacho

26

Publications

1.2K

Citations

13

H-Index

20

Concepts

All Affiliations

Cancer Research And Biostatistics Research Network (United States)Millennium Engineering and Integration (United States)Saint Vincent Health System Cedars-Sinai Medical Center

ES

About

Elber S. Camacho is an author at Cancer Research And Biostatistics specializing in oncology, medicine, and pharmacology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	4	4	258
2	Pharmacology	3	3	157
3	Health Sciences	2	2	92
4	Immunology	1	1	56
5	Pathology	1	1	101

Elber S. Camacho

×

14

Publications

1.2K

Citations

13

H-Index

	Year	Citations
Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma Sundar Jagannath, Brian G.M. Durie, Jeffrey L. Wolf, British Journal of Haematology	2005	399
Bendamustine in Patients With Rituximab-Refractory Indolent and Transformed Non-Hodgkin's Lymphoma: Results From a Phase II Multicenter, Single-Agent Study Jonathan W. Friedberg, Philip Cohen, Ling Chen, Journal of Clinical Oncology	2008	298
The current causes of death in patients with malignant melanoma Daniel R. Budman, Elber S. Camacho, Robert E. Wittes European Journal of Cancer (1965) Surgical OncologyMedicinePhotocarcinogenesisMelanomaPathology	1978	101
Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy: results of a randomized, double-blind phase III trial Cindy Weinstein, Karin Jordan, S.A. Green, Annals of Oncology	2015	80
Adjuvant methotrexate escalated to toxicity for resectable stage III and IV squamous head and neck carcinomas--a prospective, randomized study. Robert Rentschler, D. W. Wilbur, George H. Petti, Journal of Clinical Oncology Surgical OncologyMtx ToxicitySurgeryMetronomic ChemotherapyMtx Arm	1987	65
Extended follow‐up of a phase 2 trial of bortezomib alone and in combination with dexamethasone for the frontline treatment of multiple myeloma Sundar Jagannath, Brian G.M. Durie, Jeffrey L. Wolf, British Journal of Haematology Hematological MalignancyTransplantationMedicineHematologyPharmacology	2009	56
Long-Term Follow-Up of Patients Treated with Bortezomib Alone and in Combination with Dexamethasone as Frontline Therapy for Multiple Myeloma. Sundar Jagannath, Brian G.M. Durie, Jeffrey L. Wolf, Blood	2006	39
Phase 2 study of two sequential three‐drug combinations containing bortezomib, cyclophosphamide and dexamethasone, followed by bortezomib, thalidomide and dexamethasone as frontline therapy for multiple myeloma William Bensinger, Sundar Jagannath, Robert Vescio, British Journal of Haematology Hematological MalignancyOncologyTransplantationSequential Three‐drug CombinationsThree-drug Combinations	2009	36
A Phase II Study of Bortezomib (Velcade ®), Cyclophosphamide (Cytoxan®), Thalidomide (Thalomid®) and Dexamethasone as First-Line Therapy for Multiple Myeloma William Bensinger, Sundar Jagannath, Robert Vescio, Blood	2008	25
A Phase 2 Study of Bortezomib as First-Line Therapy in Patients with Multiple Myeloma. Sundar Jagannath, Durie Brian, Jeffrey L. Wolf, Blood	2004	23

Page 1